-
公开(公告)号：WO2018145076A1
公开(公告)日：2018-08-09
申请号：PCT/US2018/017028
申请日：2018-02-06
CPC分类号： G01N33/57446 , A61K31/495 , G01N33/6848 , G01N2333/91017
摘要： Methods are provided for identifying whether a tumor, and especially a colon tumor, will be responsive to treatment with the therapeutic agent temozolomide. A specific MGMT fragment peptide is precisely detected and quantitated by SRM-mass spectrometry directly in colon cancer cells collected from colon tumor tissue obtained from a cancer patient. Comparison to reference levels determines if the cancer patient will respond positively or negatively to treatment with the chemotherapeutic agent temozolomide.
-
公开(公告)号：WO2017184905A1
公开(公告)日：2017-10-26
申请号：PCT/US2017/028698
申请日：2017-04-20
CPC分类号： G01N33/57438 , G01N33/6848 , G01N2333/70596 , G01N2333/71 , G01N2333/90203 , G01N2333/90666 , G01N2560/00 , G01N2800/56
摘要： Methods are provided for determining the diagnosis of whether a liver mass is a benign hepatocellular adenoma or a pre-malignant hepatocellular dysplastic nodule and/or a malignant hepatocellular carcinoma. Specific protein fragment peptides are precisely detected and quantitated by SRM-mass spectrometry directly in liver mass cells collected from liver mass tissue that was obtained from a patient suffering from the liver mass and compared to reference levels in order to determine if the liver mass is a benign growth or a pre-cancer and/or cancer.
摘要翻译： 提供了用于确定肝脏肿块是良性肝细胞腺瘤或恶变前恶化的肝细胞发育不良结节和/或恶性肝细胞癌的诊断的方法。 通过SRM质谱法直接在从肝脏肿块组织获得的肝脏肿块细胞中精确检测和定量特异性蛋白质片段肽，所述肝脏肿瘤组织是从患有肝脏肿块的患者获得的并且与参考水平进行比较以确定肝脏肿块是否为 良性生长或癌症前期和/或癌症。
-
3.发明申请SRM/MRM ASSAY FOR THE CYCLIN-DEPENDENT KINASE INHIBITOR 2A (P16) PROTEIN 审中-公开循环依赖性激酶抑制剂2A（P16）蛋白的SRM / MRM测定
公开(公告)号：WO2016191368A1
公开(公告)日：2016-12-01
申请号：PCT/US2016/033776
申请日：2016-05-23
IPC分类号： B01D59/44 , C12Q1/37 , G01N30/06 , G01N24/00 , G01N33/559
CPC分类号： G01N33/4833 , G01N33/57484 , G01N33/6848 , G01N2333/47 , G01N2333/4704
摘要： Methods are provided for quantifying the cyclin-dependent kinase inhibitor 2A protein (p16) p16 protein directly in biological samples that have been fixed in formalin by SRM/MRM mass spectrometry. A protein sample is prepared from the biological sample using, for example, the Liquid Tissue reagents and protocol and the p16 protein is quantitated in the resulting sample by quantitating in the protein sample at least one fragment peptide from p16. Peptides can be quantitated in modified or unmodified form. An example of a modified form of a p16 peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.
摘要翻译： 提供了用于通过SRM / MRM质谱法在福尔马林中固定的生物样品中直接定量细胞周期蛋白依赖性激酶抑制剂2A蛋白（p16）p16蛋白的方法。 使用例如液体组织试剂和方案从生物样品制备蛋白质样品，并通过在蛋白质样品中定量来自p16的至少一个片段肽来定量所得样品中的p16蛋白质。 肽可以以修饰或未修饰的形式进行定量。 p16肽的修饰形式的实例是肽序列内的酪氨酸，苏氨酸，丝氨酸和/或其他氨基酸残基的磷酸化。
-
公开(公告)号：WO2012097276A2
公开(公告)日：2012-07-19
申请号：PCT/US2012/021283
申请日：2012-01-13
申请人： EXPRESSION PATHOLOGY, INC. , KRIZMAN, David, B. , HEMBROUGH, Todd , THYPARAMBIL, Sheeno , LIAO, Wei-li
IPC分类号： C12Q1/37
CPC分类号： G01N33/6893 , C07K14/4747 , C07K16/2863 , C07K16/32 , C07K2317/76 , C12Q1/485 , C12Q1/6886 , C12Q2600/158 , G01N33/5088 , G01N33/574 , G01N33/6848 , G01N2333/4703 , G01N2800/44 , G01N2800/52 , G01N2800/56
摘要： Specific peptides, and derived ionization characteristics of those peptides, from the Bcl-2-like protein 11 (BIM) are provided that are particularly advantageous for quantifying the BIM protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM). Such biological samples are chemically preserved and fixed where the biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin- fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded. A protein sample is prepared from the biological sample using the Liquid Tissue™ reagents and protocol, and the BIM protein is quantitated in the Liquid Tissue™ sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the peptides described. These peptides can be quantitated if they reside in a modified or an unmodified form. An example of a modified form of a BIM peptide is phosphorylation of a tyrosine, threonine, serine, and/or other amino acid residues within the peptide sequence.
摘要翻译： 提供了来自Bcl-2样蛋白11（BIM）的那些肽的特异性肽和衍生的电离特征，其特别有利于通过选择反应的方法在福尔马林中固定的生物样品中直接定量BIM蛋白 监测（SRM）质谱，或什么也可以称为多反应监测（MRM）。 在生物样品选自用含甲醛的试剂/固定剂（包括福尔马林固定的组织/细胞，福尔马林固定/石蜡包埋的（FFPE）组织/细胞，FFPE组织块）和 来自这些区块的细胞和已被福尔马林固定和石蜡包埋的组织培养细胞。 使用Liquid TissueTM试剂和方案从生物样品制备蛋白质样品，并且通过SRM / MRM质谱法通过在蛋白质样品中定量至少一种或多种的蛋白质样品，在Liquid TissueTM样品中定量BIM蛋白质 描述的肽。 如果它们以修饰或未修饰的形式存在，则可以定量这些肽。 BIM肽的修饰形式的实例是肽序列内的酪氨酸，苏氨酸，丝氨酸和/或其他氨基酸残基的磷酸化。
-
公开(公告)号：WO2012092531A1
公开(公告)日：2012-07-05
申请号：PCT/US2011/067998
申请日：2011-12-29
IPC分类号： C07K16/18
CPC分类号： G01N33/6848 , G01N33/574 , G01N33/6893 , G01N33/74 , G01N2333/485 , G01N2333/71 , G01N2333/912 , G01N2333/9121
摘要： The current disclosure provides for specific peptides, and derived ionization characteristics of the peptides, from the Receptor Tyrosine-Protein Kinase erbB-3, or Her3. that are particularly advantageous for quantifying the Her3 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry, or what can also be termed as Multiple Reaction Monitoring (MRM) mass spectrometry. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks, and tissue culture cells that have been formalin fixed and or paraffin embedded.
摘要翻译： 目前的公开内容提供了来自受体酪氨酸 - 蛋白激酶erbB-3或Her3的肽的特定肽和衍生的电离特征。 这特别有利于通过选择反应监测（SRM）质谱法或还可以称作多重反应监测（MRM）质谱法的方法，在已经在福尔马林中固定的生物样品中直接定量Her3蛋白。 这样的生物样品是化学保存和固定的，其中所述生物样品选自用含甲醛的试剂固定剂（包括福尔马林固定的组织/细胞，福尔马林固定/石蜡包埋的（FFPE）组织/细胞，FFPE组织块和细胞）处理的组织和细胞 从那些块和已经被福尔马林固定和石蜡包埋的组织培养细胞。
-
公开(公告)号：WO2018223112A1
公开(公告)日：2018-12-06
申请号：PCT/US2018/035788
申请日：2018-06-04
摘要： Methods are provided for identifying whether a cancer patient, and especially a gastric cancer patient, will be responsive to treatment with a sequential therapeutic strategy comprising a first administration of the FOLFIRI regimen (irinotecan/5-fluoruracil/folinic acid) followed by a separate sequential administration of the combination of the chemotherapy agents docetaxel and cisplatin (FOLFIRI + docetaxel/cisplatin). Specified TUBB3 and TYMP fragment peptides are precisely detected and quantitated by SRM-mass spectrometry directly in tumor cells, and especially gastric cancer tumor cells, that are collected from tumor tissue obtained from a cancer patient and compared to reference levels in order to determine if the cancer patients will positively respond to treatment with the sequential combination treatment of FOLFIRI + docetaxel/cisplatin.
-
7.发明申请
公开(公告)号：WO2018102827A1
公开(公告)日：2018-06-07
申请号：PCT/US2017/064562
申请日：2017-12-04
IPC分类号： G01N33/574 , G01N33/68
摘要： Methods are provided for identifying whether a lung tumor will be responsive to treatment with the combination of the therapeutic agents cisplatin and pemetrexed. Specified ERCC1, TS, p16, and FRα fragment peptides are precisely detected and quantitated by SRM-mass spectrometry directly in lung tumor cells collected from lung tumor tissue that was obtained from a cancer patient and compared to reference levels in order to determine if the lung cancer patient will positively respond to treatment with the combination of cisplatin and pemetrexed therapeutic agents.
-
公开(公告)号：WO2018089754A1
公开(公告)日：2018-05-17
申请号：PCT/US2017/061036
申请日：2017-11-10
摘要： Methods are provided for quantifying specific proteins directly in biological samples that have been fixed in formalin by SRM/MRM assay. Such biological samples are chemically preserved and fixed wherein said biological sample is selected from tissues and cells treated with formaldehyde containing agents/fixatives including formalin-fixed tissue/cells, formalin-fixed/paraffin embedded (FFPE) tissue/cells, FFPE tissue blocks and cells from those blocks. A protein digest is prepared from the biological sample using, for example, the Liquid Tissue reagents and protocol and a designated protein is quantitated in the digest sample by the method of SRM/MRM mass spectrometry by quantitating in the protein sample at least one or more of the described peptides. The proteins that can be detected and/or quantitated are CD3D, B7H3, B7-2, STATl, GBPl, GPNMB, CD27, CD3E, and CD8.
摘要翻译： 提供了用于通过SRM / MRM测定直接定量已经在福尔马林中固定的生物样品中的特定蛋白质的方法。 这些生物样品是化学保存和固定的，其中所述生物样品选自用含甲醛的试剂/固定剂（包括福尔马林固定的组织/细胞，福尔马林固定的/石蜡包埋的（FFPE）组织/细胞，FFPE组织块和 来自这些块的细胞。 使用例如液体组织试剂和方案从生物样品制备蛋白质消化物，并且通过SRM / MRM质谱法的方法在消化样品中定量指定的蛋白质，其中通过定量蛋白质样品中的至少一种或多种 的所述肽。 可被检测和/或定量的蛋白质是CD3D，B7H3，B7-2，STAT1，GBP1，GPNMB，CD27，CD3E和CD8。
-
9.发明申请
公开(公告)号：WO2018049026A3
公开(公告)日：2018-03-15
申请号：PCT/US2017/050472
申请日：2017-09-07
IPC分类号： G01N33/68
摘要： The current disclosure provides for a specific peptide, and derived ionization characteristics of a peptide from the tubulin beta-3 chain protein (TUBB3) that is particularly advantageous for quantifying the TUBB3 protein directly in biological samples that have been fixed in formalin by the method of Selected Reaction Monitoring (SRM) mass spectrometry. A protein sample is prepared from a biological sample using the Liquid Tissue reagents and protocol and the TUBB3 protein is quantitated by SRM/MRM mass spectrometry analysis of the sample, where the specific peptide is quantitated. Methods of treatment are provided in which the measured level of TUBB3 in a patient tumor sample is compared with a reference level and the patient is treated with a taxane-based treatment regimen when the measured TUBB3 level is lower than the reference level. A suitable reference level is, for example, about 700 amol/μg tissue.
摘要翻译： 目前的公开内容提供了来自微管蛋白β-3链蛋白（TUBB3）的肽的特定肽和衍生离子化特征，其特别有利于直接在生物样品中定量TUBB3蛋白，所述生物样品具有 通过选择性反应监测（SRM）质谱法的方法将其固定在福尔马林中。 使用液体组织试剂和方案从生物样品制备蛋白质样品，并通过样品的SRM / MRM质谱分析对TUBB3蛋白质进行定量，其中对特定肽进行定量。 提供了治疗方法，其中将患者肿瘤样品中TUBB3的测量水平与参考水平进行比较，并且当测量的TUBB3水平低于参考水平时，用基于紫杉烷的治疗方案治疗患者。 合适的参考水平是例如约700 amol /μg组织。
-
公开(公告)号：WO2017127703A1
公开(公告)日：2017-07-27
申请号：PCT/US2017/014371
申请日：2017-01-20
IPC分类号： A61P35/00 , C12Q1/37 , G01N33/574 , G01N33/68
CPC分类号： G01N33/574 , G01N33/57446
摘要： Methods are provided for identifying whether a tumor will be responsive to treatment with an anti-EGFR agent. Specific protein fragment peptides are precisely detected and quantitated by SRM-mass spectrometry directly in tumor cells collected from tumor tissue that was obtained from a cancer patient and compared to reference levels in order to determine if the lung cancer patient will positively respond to treatment with an anti-EGFR agent such as, for example, pamitumumab and/or erbitux.
摘要翻译： 提供了用于鉴定肿瘤是否会对用抗EGFR剂治疗有反应的方法。 通过SRM质谱法直接在从癌症患者获得的肿瘤组织中收集的肿瘤细胞中精确检测和定量特异性蛋白质片段肽并对其进行定量，并与参考水平进行比较以确定肺癌患者是否将对用 抗EGFR剂，例如帕米单抗和/或erbitux。
-
-
-
-
-
-
-
-
-
搜索结果
45 条记录 (耗时 0.017 秒)
